We are a unique partnership of investment talent and best-in-class commercial scientists
whose technologies are today valued in excess of $100BN combined.
Founding & General Partner
Alice has over a decade of investing experience, including at TPG Capital (leading global private equity firm with >$70BN AUM) and Lansdowne Partners (leading investment firm with >$15BN AUM). Her predominant investing focus has been in tech and disruptive healthcare.
Alice holds a Double First-Class degree in Mathematics, and Master’s in Mathematics/Physics from the University of Cambridge. She was a Fulbright Scholar and a Baker Scholar at Harvard Business School.
Chief Financial Officer
Peter joined Ahren in 2022 from Balderton Capital, where he was Head of Finance and supported the firm in all aspects of its financial function with a specific focus on its fund entities.
Previously, Peter was CFO and COO at a natural resources private equity fund.
Peter holds a BA (Hons) in English from Southampton University and is a qualified Chartered Accountant.
Venture Partner
Peter has over 25 years’ of investing experience, investing in and sitting on the boards of high growth businesses.
He was General Partner at Advent Venture Partners managing funds totalling £400m invested in technology and life sciences companies. He has invested in both early stage and growth stage businesses, and in a range of different sectors including software, internet, communications, and digital media. Prior to Advent, he worked for six years in the technology team at Permira. He spent his early career as a consultant with PWC and as a software developer working on MRI scanners.
Peter holds a BSc in Physics from Imperial College, London and an MBA from INSEAD. He is bilingual in French.
AI Partner
Janusz spent around a decade as Lead Scientist at DeepMind advancing the state of the art in AI and a further seven years as a Researcher at IBM Watson. Prior to joining Ahren, Janusz was Principal Scientist at Pasteur Labs & Institute for Simulation Intelligence (“ISI”), a venture backed company developing cutting edge AI-first software to simulate dynamic systems relevant across domains from energy & climate to socioeconomics and agriculture. At Pasteur Labs, Janusz led research activities on Artificial General Intelligence (“AGI”) towards reshaping scientific methods for the machine age.
Janusz obtained a PhD in Artificial Intelligence from University of Southern California, and a PhD in Mathematical Modelling and Computational Methods from the Ukraine’s State Scientific and Research Institute of Information Infrastructure.
Principal
Joanna joined Ahren in 2019 is a member of the investment team. She is responsible for the firm’s life sciences investments across stages with a particular focus on platform therapeutics, biomanufacturing and tools. She serves on the Boards of several of the firm’s European and North American portfolio companies.
Investments she is involved with include Adrestia (acq. Insmed), Biomodal, Constructive Bio, Edifice Health, Mogrify, OutSee, Ovo Labs, Pictura Bio, Rubedo Life Sciences, Switchback Systems and Zoe.
Prior to Ahren, Joanna worked at the Boston Consulting Group (BCG), where she advised multinational companies across a range of industries including healthcare.
Joanna holds a PhD in fetal immunology, focusing on childhood leukaemia, and a First-Class Master’s and undergraduate degree from the University of Oxford.
Principal
Oliver joined Ahren in 2019 and is a member of the investment team. He is responsible for the firm’s investments in applied AI across stages with a particular focus on science, education and robotics. He serves on the Boards of several of the firm’s portfolio companies in Europe, Israel and North America.
Investments he is involved with include AI21 Labs, Ambi Robotics, Bicycle Therapeutics (IPO), Bitfount, Cassidy Bio, Graphcore (acq. Softbank), Hiverge, Mentee Robotics, Micropsi Industries and Phaidra.
Prior to Ahren, Oliver was Chief of Staff at a venture backed start up recognised by Nesta as the leading British diagnostic technology to combat antimicrobial resistance.
Oliver holds a First-Class undergraduate degree in Biochemistry from the University of Exeter.
Principal
Anuj joined Ahren in 2024 and is a member of the investment team responsible for Ahren's investments in the Planet & Efficient Energy domain, as well as covering our Quantum investment opportunities. He serves on the Boards of several of the firm’s European and North American portfolio companies.
Investments he is involved in include Heirloom, New Culture, Nu Quantum, Sunfire and Velocys.
Prior to Ahren, Anuj was a Vice President in the Energy team at Jefferies Investment Bank and latterly a member of the Investment Team at Seatankers Management, the investment office of John Fredriksen, where he led business development for their NYSE-listed Energy Transition SPAC
Anuj holds a M.Sci and MA Cantab. in Natural Sciences from the University of Cambridge, with a particular focus on atmospheric chemistry.
Founding Partner
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN.
Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine.
Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Breakthrough Prize (2022), Royal Medal (2018), the Royal Society Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the American Association for Cancer Research (AACR) Academy and the Academy of Medical Sciences and a member of EMBO.
Founding Partner
Zoubin is a Vice President of Research at Google DeepMind and is the ex-Head of Google Brain. He was co-founder of Geometric Intelligence (acq. Uber) and was Chief Scientist and VP for AI at Uber.
He served as the founding Cambridge Director of the Alan Turing Institute, the UK’s national institute for data science and AI, and as a Director of the Leverhulme Centre for the Future of Intelligence.
Zoubin was elected a Fellow of the Royal Society for his contributions to machine learning, is the winner of the 2021 Royal Society Milner Award for outstanding achievements in computer science in Europe, is a Turing AI World Leading Researcher Fellow and led The Future of Compute Review for UK Government. He was named in 2016 as one of the Top Ten Most Influential Scholars in Machine Learning. He has served as advisor to Microsoft, VocalIQ (acq. Apple) and several other companies.
Founding Partner
Sir Steve is the Originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN, and used to treat 140,000 patients worldwide with ovarian, breast, pancreatic and prostate cancer.
Sir Steve is a repeat entrepreneur, and most recently founded Adrestia Therapeutics with Ahren in 2018, an early-stage drug discovery platform, which was acquired by Insmed Inc in 2023.
Sir Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is Senior Group Leader at the Cancer Research UK Cambridge Institute and Associate Group Leader at the Gurdon Institute. He is a leading expert in the field of DNA repair and DNA-damage signalling and invented Lynparza, the world’s first marketed DNA-repair enzyme inhibitor, an effective treatment of breast and other cancers.
Sir Steve’s awards include the Johann Anton Merck Award (2022), Royal Society Mullard Award (2020), Heineken Prize for Science by the Royal Netherlands Academy of Arts and Science (2016) and the UK GSN Medal for his contributions to the field of genome stability. He is a fellow of the Royal Society and a member of EMBO.
Founding Partner
Andy is a CERN leader and Head of the Cavendish Laboratory (Physics Department) at the University of Cambridge.
Andy is a Professor of High Energy Physics at the University of Cambridge and Head of the Physics Department. He is an expert in high energy physics, extraspace dimensions, quantum-sized black holes and supersymmetry, with over 500 publications to his name. He is a founder of the ATLAS experiment for the Large Hadron Collider and has commercially developed silicon detectors, fast electronics, large software systems and pattern recognition, and he has pioneered computational radiotherapy and artificial photosynthesis. Andy’s awards include the Pilkington Prize for excellence.
Founding Partner
Sir Venki is a Nobel Laureate and was previously President of the Royal Society, the UK’s premier science body.
Sir Venki received the 2009 Nobel Prize in Chemistry for his work that led to solving the atomic structure of the ribosome and has also worked on histone and chromatin structures, which help us to understand how DNA is organised in cells.
Sir Venki is a Group Leader at the MRC Laboratory of Molecular Biology in Cambridge. He was knighted in 2012 and his further awards include the Heatley Medal of the British Biochemical Society. He is a Member of the US National Academy of Sciences, Leopoldina and EMBO, and a Foreign Member of the Indian National Science Academy.
Founding Partner
Lord Martin Rees is a world-renowned astrophysicist, Astronomer Royal, founder of CSER, former President of the Royal Society and former Master of Trinity College, University of Cambridge.
Lord Martin Rees is a world-leading cosmologist and astrophysicist. He has been Astronomer Royal since 1995 and was Master of Trinity College, Cambridge from 2004 to 2012 and President of the Royal Society between 2005 and 2010.
Lord Rees is the author of more than 500 research papers, and he has made important contributions to the origin of cosmic microwave background radiation, as well as to galaxy clustering and formation. His studies of the distribution of quasars led to final disproof of Steady State theory. In addition to his scientific interests, Lord Rees has written and spoken extensively about the interfaces between science, ethics and politics. He is a member of the Board of the Institute for Advanced Study in Princeton, the Oxford Martin School and the Gates Cambridge Trust. He co-founded the Centre for the Study of Existential Risk and serves on the Scientific Advisory Board for the Future of Life Institute.
Founding Partner
Sir Gregory is a Nobel Laureate, inventor of the technology leading to Humira (c.$20BN revenue in 2018, the world’s greatest grossing drug) and founder of three companies. He is a former Master of Trinity College, University of Cambridge.
Sir Gregory is the inventor of the technology that led to Humira (Adalimumab), the first fully human antibody blockbuster and the best-selling drug worldwide. He was awarded the 2018 Nobel Prize for his pioneering work in using phage display for the directed evolution of antibodies, with the aim of producing new therapeutics. Sir Gregory’s development of technologies for making pharmaceutical antibodies by genetic engineering have led to many of the world’s top-selling pharmaceutical treatments for cancer and immune disorders, also including the “humanised” antibodies Herceptin (for treatment of breast cancer) and Lucentis (for treatment of wet acute macular degeneration). In order to see his technologies applied, Sir Gregory founded several successful start-up companies.
Sir Gregory sits on the board of Ahren’s portfolio companies Constructive Bio and Bicycle Therapeutics.
Sir Gregory was knighted for his services to Molecular Biology in 2004 and his other awards include a Royal Medal in 2011 and the Nobel Prize for Chemistry in 2018. Sir Gregory is a Fellow of the Royal Society.
Science Partner
Roberto is a Professor of Information Engineering at the University of Cambridge with expertise in computer vision and robotics. He has helped support several successful start-ups.
Roberto was awarded his D.Phil. (PhD) in Computer Vision from the University of Oxford and was a Toshiba Fellow and engineer at the Toshiba Corporation Research and Development Centre in Kawasaki, Japan. He joined the Department of Engineering, University of Cambridge in 1992 and is a Fellow of Jesus College. He is a Fellow of the Royal Academy of Engineering.
Roberto’s domains of expertise include the recovery of motion and 3D shape of visible surfaces from image sequences; object detection and recognition; novel man-machine interfaces using hand, face and body gestures; real-time visual tracking for localisation and robot guidance; applications of computer vision in mobile phones, visual inspection and image-retrieval and video search. He has authored 2 books, edited 12 volumes and co-authored more than 400 papers. Several of his students have spun out highly successful start-ups.
Advisor
David is Co-President of Clayton Dubilier & Rice, where he has worked for 23 years and is a member of the Investment Committee. Based in London, he is responsible for the Firm’s European business. He is personally responsible for investments in B&M Retail, BCA, Belron, BUT, Kalle Group, Mauser Group, Motor Fuel Group, and Westbury Street Holdings, and played a key role in many others. Previously, David worked in the private equity and investment banking divisions of Morgan Stanley.
David holds a BA in Economics from Amherst College and is a graduate of Harvard Business School.
Founding & General Partner
Chief Financial Officer
Venture Partner
AI Partner
Principal
Principal
Principal
Founding Partner
Founding Partner
Founding Partner
Founding Partner
Founding Partner
Founding Partner
Founding Partner
Science Partner
Advisor
